A Noval ADC for DLBCL Get Accelerated Approval
Recently, the United States Food and Drug Administration announced the accelerated approval of the antibody-conjugate drug (ADC) Polivy (polatuzumab vedotin-piiq) for the treatment of refractory adult patients with diffuse large B-cell lymphomaRead More…